Posts in the “Treatment Options Treatment Options” category:

Chest radiation may be useful for combatting advanced lung cancers

Posted by Samantha Powell on September 18th, 2014 |

Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50 percent, European researchers report. The research was published online Sept. 14 in The Lancet to coincide with presentation at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14… Read More

Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac

Posted by Samantha Powell on September 17th, 2014 |

A little more than two months after inking a licensing deal with Sanofi ($SNY), CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also includes up to about $556 million in prospective milestones for the German biotech. In exchange for… Read More

Yale study sees benefits of traditional lung cancer surgery

Posted by Samantha Powell on September 17th, 2014 |

Traditional surgery appears to save lives better than radiosurgery, even though it’s more invasive, when treating early-stage non-small cell lung cancer, according to Yale University. A study of 1,078 lung cancer patients’ Medicare billing records showed this to be true even considering the risks of regular surgery. “What was dramatic to me was the relatively… Read More

FDA Approves Merck’s New-Wave Cancer Drug

Posted by Samantha Powell on September 4th, 2014 |

U.S. regulators on Thursday approved a new kind of cancer drug from Merck MRK +1.68% & Co. that is designed to unleash the body’s immune system against tumors. The drug is part of a long-anticipated wave of medicines that could transform cancer treatment and forge a large new market for pharmaceutical companies. The Food and… Read More

Powerful New Cancer Drugs Offer Hope—at Steep Cost

Posted by Samantha Powell on September 3rd, 2014 |

The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 a patient, a harbinger of hefty prices the new drugs are expected to command in the U.S. and Europe in coming months. The drug Opdivo, from Ono Pharmaceutical Co. 4528.TO -2.06%… Read More

MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease

Posted by Samantha Powell on August 14th, 2014 |

The University of Texas MD Anderson Cancer Center announced today an alliance with Cambridge, MA-based Foundation Medicine. The teams are opening a randomized-controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease. This study… Read More

Do you really need that medical test or treatment?

Posted by Samantha Powell on August 4th, 2014 |

For some time there has been a nationwide effort to cut back on unnecessary medical tests, over-prescribed drugs and surgery that doesn’t end up helping people feel better. But old habits die hard. Dr. Emma Trejo knows that only too well. As an internist practicing in the South Bay city of Lawndale, she says patients… Read More

Possible Advance for Some Late-Stage Lung Cancer Patients

Posted by Samantha Powell on July 8th, 2014 |

Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations, a new small study reveals. In many cases, surgical biopsy is too dangerous for these patients, so less-invasive methods are used, including fine-needle aspiration and core needle… Read More

Gibbs Cancer Center selected to test new drugs for lung cancer

Posted by Samantha Powell on July 2nd, 2014 |

The Gibbs Cancer Center and Research Institute in Spartanburg has been selected as one of the first 10 sites in the world to test new drugs that target the type of lung cancer often associated with smoking. Patients who meet eligibility requirements will be administered the drugs based on a 200-gene profile, which uses biomarkers… Read More

Ambitious ‘Lung-MAP’ Trial Aims to Evaluate Biomarkers and New Drugs in Squamous Cell Lung Cancer

Posted by Samantha Powell on June 23rd, 2014 |

This month, the National Cancer Institute (NCI), along with the FDA, the Southwest Oncology Group (SWOG), several private foundations and five pharmaceutical companies, launched a prospective, biomarker-driven study of new drugs for squamous cell lung cancer. The Lung-MAP trial is remarkable for its collaborative nature, and scope. The study will identify “actionable” molecular abnormalities in… Read More